

Press Release

## TRIAGENICS, INC.

---

Contact: Leigh Colby, TriAgenics, Inc  
541.527.1800

**FOR IMMEDIATE RELEASE**  
June 30, 2023

### **TriAgenics Developing Surgery-Free Wisdom Tooth Bud Ablation Treatment**

#### **Latest Research Demonstrates Success Using High-Precision CT-Guided Tumor Treatment to Prevent Wisdom Tooth Formation**

**REDMOND, Ore.** — Imagine a one-minute, surgery-free treatment that stops wisdom teeth from ever forming. New research published in *[The Journal of Oral and Maxillofacial Surgery](#)* shows that oral health and development firm [TriAgenics, Inc.](#) is working to make this a reality.

TriAgenics' CEO Leigh Colby, D.D.S., believes this research is the future of wisdom teeth management for patients ages 7-11. Efforts are now underway to generate additional investment, obtain FDA approval, and bring this new treatment to market as soon as possible, he said.

“Based on our extensive research, we believe this will simplify the headache of wisdom tooth management for dentists. This is an area of dentistry that has remained largely unchanged for the past 100 years,” said Colby. “We expect there will be no recovery time, no dry socket, and none of the pain compared to having wisdom teeth removed. Long-term outcomes are expected to be far better than allowing these troublesome teeth to form.”

With a 100% success rate at blocking molar formation in animal trials, TriAgenics is targeting first sales of its Zero3 treatment kits in 2024.

The organization's business model is similar to how Align Technology manufactures and delivers its clear braces. Licensed dentists will send TriAgenics their patients' x-rays and prescriptions for Zero3 TBA treatment. TriAgenics will then fabricate custom 3TBA surgical kits and send them to dentists to perform the 3TBA treatment.

Total U.S. expenditures associated with extracting wisdom teeth are estimated to be worth nearly \$5 billion, when imaging and sedation costs are factored in. TriAgenics estimates its total addressable market to be greater than \$2.5 billion annually for Zero3 TBA.

TriAgenics believes it has a lock on the North American market through a strong IP position that includes 23 U.S. and international patents. The company has previously raised \$7.5 million through

Series A1 and A2 offerings. It is now offering Series A3 stock through [Start Engine](#).

###

**About**

TriAgenics, Inc. is an oral health and development firm based in Redmond, Oregon (USA). For more information call (541) 527-1800, email [contact@triagenics.com](mailto:contact@triagenics.com), or visit [www.triagenics.com](http://www.triagenics.com).